Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Anti-MAG Neuropathy
NCT05136976Phase 3Recruiting
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2023
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-myelin-associated glycoprotein neuropathy comparing Rituximab with Placebo (2 arms). Primary endpoint: Inflammatory Rasch-built Overall Disability Scale at 12 months. Started Jun 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on NCT05136976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136976.